The Phase 2a trial data for IMM-1-104 represents a significant breakthrough in pancreatic cancer treatment. The 43% overall response rate (ORR) and 86% disease control rate (DCR) in combination with modified gemcitabine/nab-paclitaxel substantially outperform historical benchmarks of 23% ORR and 48% DCR. The 100% tumor reduction in the FOLFIRINOX combination arm and 67% reduction in monotherapy demonstrate remarkable efficacy across multiple treatment settings.
The tolerability profile is particularly noteworthy - the absence of Grade 3/4 adverse events in the monotherapy arm suggests a potential paradigm shift in MEK inhibition. This could enable broader combination strategies and longer treatment durations, critical factors in improving patient outcomes. Immuneering's Cancer Drug Shows Stunning 43% Response Rate in Pancreatic Cancer Trial
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only.
Read more